IGHCCND1 MANTLE CELL LYMPHOMA,BLOOD & BONE MARROW

What is Mantle Cell Lymphoma, IGH/CCND1 test?

Mantle cell lymphoma (MCL), IGH/CCND1 test is a molecular cytogenetic test used to detect the t(11;14)(q13;q32) chromosomal translocation, which fuses the CCND1 (cyclin D1) gene on chromosome 11 with the IGH (immunoglobulin heavy chain) gene on chromosome 14. This translocation leads to overexpression of cyclin D1, a protein that promotes uncontrolled cell proliferation, and is a hallmark feature of mantle cell lymphoma, a type of B-cell non-Hodgkin lymphoma. Mantle cell lymphoma (MCL), IGH/CCND1 test is usually performed using Fluorescence In Situ Hybridization (FISH) on blood or bone marrow samples.

Why consider mantle cell lymphoma, IGH/CCND1 test?

Mantle Cell Lymphoma, IGH/CCND1 test can be considered for

• To confirm the diagnosis of mantle cell lymphoma through detection of its characteristic genetic marker.
• To differentiate MCL from other B-cell lymphomas, especially chronic lymphocytic leukemia (CLL) or diffuse large B-cell lymphoma (DLBCL).
• To assess prognosis and predict disease behavior, as cyclin D1 overexpression is associated with aggressive growth.
• To monitor disease progression or response to therapy.

Who should get tested for mantle cell lymphoma, IGH/CCND1 test?

Mantle cell lymphoma, IGH/CCND1 test is generally recommended for:

• Patients with suspected or confirmed mantle cell lymphoma.
• Individuals with abnormal lymphocytes in blood or bone marrow suggestive of MCL.
• Cases requiring molecular confirmation of the t(11;14) translocation for diagnosis and treatment planning.
• Patients undergoing risk stratification or monitoring during therapy.

More Information

Other Names: IGH/CCND1 Fusion Gene Test, t(11;14)(q13;q32) Translocation Study, Mantle Cell Lymphoma FISH Panel, Cyclin D1 Rearrangement Test

Mantle Cell Lymphoma (MCL) is a rare and aggressive type of B-cell non-Hodgkin lymphoma that arises from B lymphocytes in the “mantle zone” of lymphoid follicles. It accounts for about 5–7% of all non-Hodgkin lymphomas and primarily affects older adults.  Mantle cell lymphoma is considered aggressive but may have variable clinical behavior, with some patients showing slower progression (indolent forms).